Us Department of Labor, Office of Workers' Compensation Programs
Total Page：16
File Type：pdf, Size：1020Kb
Load more
Recommended publications
-
The Structure and Function of Breathing
CHAPTERCONTENTS The structure-function continuum 1 Multiple Influences: biomechanical, biochemical and psychological 1 The structure and Homeostasis and heterostasis 2 OBJECTIVE AND METHODS 4 function of breathing NORMAL BREATHING 5 Respiratory benefits 5 Leon Chaitow The upper airway 5 Dinah Bradley Thenose 5 The oropharynx 13 The larynx 13 Pathological states affecting the airways 13 Normal posture and other structural THE STRUCTURE-FUNCTION considerations 14 Further structural considerations 15 CONTINUUM Kapandji's model 16 Nowhere in the body is the axiom of structure Structural features of breathing 16 governing function more apparent than in its Lung volumes and capacities 19 relation to respiration. This is also a region in Fascla and resplrstory function 20 which prolonged modifications of function - Thoracic spine and ribs 21 Discs 22 such as the inappropriate breathing pattern dis- Structural features of the ribs 22 played during hyperventilation - inevitably intercostal musculature 23 induce structural changes, for example involving Structural features of the sternum 23 Posterior thorax 23 accessory breathing muscles as well as the tho- Palpation landmarks 23 racic articulations. Ultimately, the self-perpetuat- NEURAL REGULATION OF BREATHING 24 ing cycle of functional change creating structural Chemical control of breathing 25 modification leading to reinforced dysfunctional Voluntary control of breathing 25 tendencies can become complete, from The autonomic nervous system 26 whichever direction dysfunction arrives, for Sympathetic division 27 Parasympathetic division 27 example: structural adaptations can prevent NANC system 28 normal breathing function, and abnormal breath- THE MUSCLES OF RESPIRATION 30 ing function ensures continued structural adap- Additional soft tissue influences and tational stresses leading to decompensation. -
Vertebral Column and Thorax
Introduction to Human Osteology Chapter 4: Vertebral Column and Thorax Roberta Hall Kenneth Beals Holm Neumann Georg Neumann Gwyn Madden Revised in 1978, 1984, and 2008 The Vertebral Column and Thorax Sternum Manubrium – bone that is trapezoidal in shape, makes up the superior aspect of the sternum. Jugular notch – concave notches on either side of the superior aspect of the manubrium, for articulation with the clavicles. Corpus or body – flat, rectangular bone making up the major portion of the sternum. The lateral aspects contain the notches for the true ribs, called the costal notches. Xiphoid process – variably shaped bone found at the inferior aspect of the corpus. Process may fuse late in life to the corpus. Clavicle Sternal end – rounded end, articulates with manubrium. Acromial end – flat end, articulates with scapula. Conoid tuberosity – muscle attachment located on the inferior aspect of the shaft, pointing posteriorly. Ribs Scapulae Head Ventral surface Neck Dorsal surface Tubercle Spine Shaft Coracoid process Costal groove Acromion Glenoid fossa Axillary margin Medial angle Vertebral margin Manubrium. Left anterior aspect, right posterior aspect. Sternum and Xyphoid Process. Left anterior aspect, right posterior aspect. Clavicle. Left side. Top superior and bottom inferior. First Rib. Left superior and right inferior. Second Rib. Left inferior and right superior. Typical Rib. Left inferior and right superior. Eleventh Rib. Left posterior view and left superior view. Twelfth Rib. Top shows anterior view and bottom shows posterior view. Scapula. Left side. Top anterior and bottom posterior. Scapula. Top lateral and bottom superior. Clavicle Sternum Scapula Ribs Vertebrae Body - Development of the vertebrae can be used in aging of individuals. -
Lactobacillus Acidophilus Nucelic Acid Sequences Encoding Carbohydrate Utilization-Related Proteins and Uses Therefor
(19) & (11) EP 2 407 481 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 18.01.2012 Bulletin 2012/03 C07K 14/335 (2006.01) C12N 15/31 (2006.01) C12N 15/54 (2006.01) C12N 9/12 (2006.01) (2006.01) (2006.01) (21) Application number: 11176351.2 C12N 15/74 C12Q 1/37 (22) Date of filing: 08.03.2005 (84) Designated Contracting States: • Russel, Michael W. AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Newburgh, IN 47630 (US) HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR • Duong, Tri Raleigh, North Carolina 27606 (US) (30) Priority: 08.03.2004 US 551121 P 07.03.2005 US 74226 (74) Representative: Williams, Aylsa D Young & Co LLP (62) Document number(s) of the earlier application(s) in 120 Holborn accordance with Art. 76 EPC: London EC1N 2DY (GB) 10196268.6 / 2 348 041 05760391.2 / 1 727 826 Remarks: •Thecomplete document including Reference Tables (71) Applicant: North Carolina State University and the Sequence Listing can be downloaded from Raleigh, North Carolina 27606 (US) the EPO website •This application was filed on 02-08-2011 as a (72) Inventors: divisional application to the application mentioned • Klaenhammer, Todd Robert under INID code 62. Raleigh, NC 27606 (US) •Claims filed after the date of filing of the application/ • Altermann, Eric after the date of receipt of the divisional application Apex, NC 27539 (US) (Rule 68(4) EPC). • Barrangou, Rodolphe Madison, WI 53718 (US) (54) Lactobacillus acidophilus nucelic acid sequences encoding carbohydrate utilization-related proteins and uses therefor (57) Carbohydrate utilization-related and multidrug invention also provides vectors containing a nucleic acid transporter nucleic acids and polypeptides, and frag- of the invention and cells into which the vector has been ments and variants therof, are disclosed in the current introduced. -
Soonerstart Automatic Qualifying Syndromes and Conditions 001
SoonerStart Automatic Qualifying Syndromes and Conditions 001 Abetalipoproteinemia 272.5 002 Acanthocytosis (see Abetalipoproteinemia) 272.5 003 Accutane, Fetal Effects of (see Fetal Retinoid Syndrome) 760.79 004 Acidemia, 2-Oxoglutaric 276.2 005 Acidemia, Glutaric I 277.8 006 Acidemia, Isovaleric 277.8 007 Acidemia, Methylmalonic 277.8 008 Acidemia, Propionic 277.8 009 Aciduria, 3-Methylglutaconic Type II 277.8 010 Aciduria, Argininosuccinic 270.6 011 Acoustic-Cervico-Oculo Syndrome (see Cervico-Oculo-Acoustic Syndrome) 759.89 012 Acrocephalopolysyndactyly Type II 759.89 013 Acrocephalosyndactyly Type I 755.55 014 Acrodysostosis 759.89 015 Acrofacial Dysostosis, Nager Type 756.0 016 Adams-Oliver Syndrome (see Limb and Scalp Defects, Adams-Oliver Type) 759.89 017 Adrenoleukodystrophy, Neonatal (see Cerebro-Hepato-Renal Syndrome) 759.89 018 Aglossia Congenita (see Hypoglossia-Hypodactylia) 759.89 019 Albinism, Ocular (includes Autosomal Recessive Type) 759.89 020 Albinism, Oculocutaneous, Brown Type (Type IV) 759.89 021 Albinism, Oculocutaneous, Tyrosinase Negative (Type IA) 759.89 022 Albinism, Oculocutaneous, Tyrosinase Positive (Type II) 759.89 023 Albinism, Oculocutaneous, Yellow Mutant (Type IB) 759.89 024 Albinism-Black Locks-Deafness 759.89 025 Albright Hereditary Osteodystrophy (see Parathyroid Hormone Resistance) 759.89 026 Alexander Disease 759.89 027 Alopecia - Mental Retardation 759.89 028 Alpers Disease 759.89 029 Alpha 1,4 - Glucosidase Deficiency (see Glycogenosis, Type IIA) 271.0 030 Alpha-L-Fucosidase Deficiency (see Fucosidosis) -
Metabolism of Levulinate and Conversion to the Drug Of
METABOLISM OF LEVULINATE AND CONVERSION TO THE DRUG OF ABUSE 4-HYDROXYPENTANOATE by STEPHANIE R. HARRIS Submitted in partial fulfillment of the requirements For the Degree of Doctor of Philosophy Thesis Advisor: Henri Brunengraber, M.D., Ph.D. Department of Nutrition CASE WESTERN RESERVE UNIVERSITY August 2011 CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We hereby approve the thesis/dissertation of STEPHANIE R. HARRIS candidate for the ________________________________ Doctor of Philosophy degree *. (signed) ________________________________________________ Edith Lerner, PhD (Chair of the committee) ________________________________________________ Henri Brunengraber, MD, PhD ________________________________________________ Colleen Croniger, PhD ________________________________________________ Paul Ernsberger, PhD ________________________________________________ Janos Kerner, PhD ________________________________________________ Michelle Puchowicz, PhD (date) _______________________June 16, 2011 *We also certify that written approval has been obtained for any proprietary material contained therein. ii DEDICATION I dedicate this work to my parents and to my husband, Paul. My parents have provided continuous love, encouragement, and guidance throughout my life. They have taught me to set my goals high. My husband has been a source of strength and inspiration, and his dedication and enthusiastic support have helped me achieve this work. iii TABLE OF CONTENTS Table of Contents………………………………………………………………………... iv List of Tables…………………………………………………………………………....viii -
Bilateral Same-Day Laser Peripheral Iridotomy in the Philadelphia Glaucoma Detection and Treatment Project
ORIGINAL STUDY Bilateral Same-day Laser Peripheral Iridotomy in the Philadelphia Glaucoma Detection and Treatment Project Michael Waisbourd, MD,* Anousheh Shafa, BS,* Radha Delvadia, BS,* Harjeet Sembhi, MPH,* Jeanne Molineaux, COA,* Jeffery Henderer, MD,w Laura T. Pizzi, PharmD, MPH,z Jonathan S. Myers, MD,* Lisa A. Hark, PhD, RD,* and L. Jay Katz, MD* reported in 2 patients (3%) and glare in 1 patient (1.5%). Thirteen Purpose: To report the outcomes of bilateral, same-day laser patients (19.7%) had repeat LPI treatment. All patients success- peripheral iridotomy (LPI) in the Philadelphia Glaucoma Detec- fully tolerated LPI treatment without serious complications. tion and Treatment Project. Conclusions: Performing bilateral, same-day LPI was well tolerated Methods: The Philadelphia Glaucoma Detection and Treatment in a large community-based, glaucoma detection and treatment Project was a community-based initiative aimed to improve project. Applying this treatment strategy may be considered in detection, management, treatment, and follow-up care of individ- similar settings, where patients’ access to eye care is limited and it uals at high risk for glaucoma. This novel project performed LPI, may be a cost-effective strategy. where 2 eyes received laser therapy on the same day. Of the 1649 patients examined between January 1, 2013 and May 31, 2014, Key Words: glaucoma detection, angle closure, laser peripheral patients who underwent bilateral, same-day LPI were included in iridotomy, bilateral same-day ocular procedures our analysis. Main outcome measures were visual acuity, intra- (J Glaucoma 2016;25:e821–e825) ocular pressure (IOP), and postoperative complication rates. Results: A total of 132 eyes of 66 patients underwent bilateral, aser iridotomy is aimed to eliminate the relative pupil- same-day LPI. -
Large Animal Surgical Procedures As-Of December 1, 2020 Abdominal
Large Animal Surgical Procedures as-of December 1, 2020 Core Curriculum Category Surgical Category Surgical Procedure Diaphragmatic herniorrhaphy Exploratory celiotomy - left flank Exploratory celiotomy - right flank Abdominal cavity/wall Exploratory celiotomy - ventral midline Exploratory celiotomy - ventral paramedian Exploratory laparotomy - death / euthanasia on table Peritoneal lavage via celiotomy Cecocolostomy Ileo-/Jejunocolostomy Cecum Jejunocecostomy Typhlectomy, partial Typhlotomy Abomasopexy, laparoscopic Abomasopexy, left flank Abdominal - LA Abomasopexy, paramedian Food animal GI: Abomasum Abomasotomy Omentopexy Pyloropexy, flank Reduction of volvulus Typhlectomy Food animal GI: Cecum Typhlotomy Food animal GI: Descending colon, Rectal prolapse, amputation/anastomosis rectum Rectal prolapse, submucosal reduction Food animal GI: Rumen Rumenotomy Decompression/emptying (no enterotomy) Food animal GI: Small intestine Enterotomy Reduction w/o resection (incarceration, volvulus, etc.) Resection/anastomosis Enterotomy Reduction of displacement Food animal GI: Spiral colon Reduction of volvulus Resection/anastomosis (inc. atresia coli) Side-side anastomosis, no resection Colopexy, hand-sutured Colopexy, laparoscopic Colostomy Large colon Enterotomy Reduction of displacement Reduction of volvulus Resection/anastomosis Biopsy Liver Cholelith removal Liver lobectomy Laceration repair Rectum Rectal prolapse repair Resection/anastomosis Enterotomy Impaction resolution via celiotomy Small colon Resection/anastomosis Taeniotomy Decompression/emptying -
Breast Reconstruction with Expanders and Implants
Evidence-Based Clinical Practice Guideline: Breast Reconstruction with Expanders and Implants INTRODUCTION Disclaimer Evidence-based guidelines are strategies for patient management, The American Cancer Society estimates that nearly 230,000 American developed to assist physicians in clinical decision making. This women were diagnosed with invasive breast cancer in 2011.1 Many of guideline was developed through a comprehensive review of the these individuals will require mastectomy and total reconstruction of scientific literature and consideration of relevant clinical experience, the breast. The diagnosis and subsequent process can create signifi- and describes a range of generally acceptable approaches to diagnosis, cant confusion and distress for the affected persons and their families management, or prevention of specific diseases or conditions. This and, consequently, surgical treatment and reconstructive procedures guideline attempts to define principles of practice that should are of utmost importance in the breast cancer care continuum. In generally meet the needs of most patients in most circumstances. 2011, the American Society of Plastic Surgeons® (ASPS) reported an increase in the rate of breast reconstructions, citing nearly 100,000 However, this guideline should not be construed as a rule, nor procedures, of which the majority employed expanders/implants.2 should it be deemed inclusive of all proper methods of care The 3% increase in reconstructions over the course of just one year or exclusive of other methods of care reasonably directed at highlights the significance of maintaining patient safety and obtaining the appropriate results. It is anticipated that it will be optimizing surgical outcomes. necessary to approach some patients’ needs in different ways. -
Special Considerations in Cataract Surgery: Five Cornea Challenges
Clinical Update EXTRA CONTENT AVAILABLE CATARACT Special Considerations in Cataract Surgery: Five Cornea Challenges by linda roach, contributing writer interviewing preston h. blomquist, md, rosa a. braga-mele, md, kimberly a. drenser, md, phd, herbert e. kaufman, md, marguerite mcdonald, md, and roger f. steinert, md s the most common surgical choices, said Marguerite McDonald, IOL Selection procedure in ophthalmol- MD, of Lynbrook, N.Y. The device en- ogy, replacement of a cloudy ables the surgeon to directly measure 1 crystalline lens with an the eye’s aphakic refractive power in intraocular lens (IOL) usu- the operating room. Aally presents the ophthalmologist with Using intraoperative aberrometry is familiar sets of surgical routines. But becoming more commonplace, as “it what about those cases that involve may help in achieving more accuracy comorbidities or other complicating with IOL power selection,” Dr. Mc- factors? Donald said. Several experts shared their per- Tips on IOL selection. The chosen spectives on approaching out-of-the- IOL should be shaped to neutralize After an off-center LASIK procedure ordinary cataract surgeries in ways spherical aberrations, said Rosa A. such as this, the irregularity of the that offer the best chance at optimiz- Braga-Mele, MD, at the University of corneal topography indicates that a ing patient outcomes. This month, Toronto. “In anybody who has had multifocal IOL should be avoided. here’s a look at five challenges involv- myopic LASIK or PRK, I think it’s very ing the cornea. important to use a negatively aspheric prior to cataract surgery. 2) A dysfunc- IOL, because these patients have more tional, unstable tear film will affect the Challenge: Prior Refractive Surgery positively aberrant corneas. -
Surgical Options for Breast Cancer
The Breast Center Smilow Cancer Hospital 20 York Street, North Pavilion New Haven, CT 06510 Phone: (203) 200-2328 Fax: (203) 200-2075 SURGICAL OPTIONS There are a number of surgical procedures available today for the treatment of breast cancer. You will likely have a choice and will need to make your own decision, in consultation with your specific surgeon, about the best option for you. We offer you a choice because the research on the treatment of breast cancer has clearly shown that the cure and survival rates are the same regardless of what you choose. The choices can be divided into breast conserving options (i.e. lumpectomy or partial mastectomy) or breast removing options (mastectomy). A procedure to evaluate your armpit (axillary) lymph nodes will likely occur at the same time as your breast surgery. This is done to help determine the likelihood that cells from your breast cancer have left the breast and spread (metastasized) to another more dangerous location. This information will be used to help decide about your need for chemotherapy or hormone blocking drugs after surgery. PARTIAL MASTECTOMY (LUMPECTOMY) A partial mastectomy involves removing the cancer from your breast with a rim, or margin, of normal breast tissue. This allows the healthy noncancerous part of your breast to be preserved, and usually will not alter the sensation of the nipple. The benefit of this surgical choice is that it often preserves the cosmetics of the breast. Your surgeon will make a decision about the volume of tissue that needs removal in order to maximize the chance of clear margins as confirmed by our pathologist. -
Diagnostic Nasal/Sinus Endoscopy, Functional Endoscopic Sinus Surgery (FESS) and Turbinectomy
Medical Coverage Policy Effective Date ............................................. 7/10/2021 Next Review Date ....................................... 3/15/2022 Coverage Policy Number .................................. 0554 Diagnostic Nasal/Sinus Endoscopy, Functional Endoscopic Sinus Surgery (FESS) and Turbinectomy Table of Contents Related Coverage Resources Overview .............................................................. 1 Balloon Sinus Ostial Dilation for Chronic Sinusitis and Coverage Policy ................................................... 2 Eustachian Tube Dilation General Background ............................................ 3 Drug-Eluting Devices for Use Following Endoscopic Medicare Coverage Determinations .................. 10 Sinus Surgery Coding/Billing Information .................................. 10 Rhinoplasty, Vestibular Stenosis Repair and Septoplasty References ........................................................ 28 INSTRUCTIONS FOR USE The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence -
Breast Cancer Treatment What You Should Know Ta Bl E of C Onte Nts
Breast Cancer Treatment What You Should Know Ta bl e of C onte nts 1 Introduction . 1 2 Taking Care of Yourself After Your Breast Cancer Diagnosis . 3 3 Working with Your Doctor or Health Care Provider . 5 4 What Are the Stages of Breast Cancer? . 7 5 Your Treatment Options . 11 6 Breast Reconstruction . 21 7 Will Insurance Pay for Surgery? . 25 8 If You Don’t Have Health Insurance . 26 9 Life After Breast Cancer Treatment . 27 10 Questions to Ask Your Health Care Team . 29 11 Breast Cancer Hotlines, Support Groups, and Other Resources . 33 12 Definitions . 35 13 Notes . 39 1 Introducti on You are not alone. There are over three million breast cancer survivors living in the United States. Great improvements have been made in breast cancer treatment over the past 20 years. People with breast cancer are living longer and healthier lives than ever before and many new breast cancer treatments have fewer side effects. The New York State Department of Health is providing this information to help you understand your treatment choices. Here are ways you can use this information: • Ask a friend or someone on your health care team to read this information along with you, or have them read it and talk about it with you when you feel ready. • Read this information in sections rather than all at once. For example, if you have just been diagnosed with breast cancer, you may only want to read Sections 1-4 for now. Sections 5-8 may be helpful while you are choosing your treatment options, and Section 9 may be helpful to read as you are finishing treatment.